Allogene Therapeutics

In October of 2024, I was diagnosed with Non Hodgkins Lymphoma. I’m excited to share that I’m on the cover of @mediaplanetusa and @usatoday Blood Health campaign, out today! ?? With blood cancers like leukemia, lymphoma, and multiple myeloma affecting thousands every year, raising awareness and providing actionable information has never been more important. This campaign shines a light on the latest advancements in blood cancer treatment, stories of resilience, and ways to advocate for your health. Together, we can empower patients, support families, and drive progress in the fight against blood cancers. READ MY STORY HERE: https://lnkd.in/gs3Td3vZ #BloodHealth #CancerAwareness #Advocacy #Empowerment #Leukemia #Lymphoma #MultipleMyeloma

We’re excited to introduce the launch of #BloodHealth, a campaign focused on the serious nature of blood disorders, cancers, and bleeding conditions. Our goal is to raise awareness, improve access to life-saving treatments, and offer real hope to those battling these diseases. With the voices of experts and patient advocates, we’re ensuring that individuals affected by blood health conditions have the resources and support they need to thrive. Check it out in USA TODAY and online https://lnkd.in/gfSTXcAc Thank you to our partners! Dave Coulier, John J. York, Belinda Avalos, MD, President, ASH, Joseph Mikhael, MD, Chief Medical Officer, IMF, Katharina Harf, Chairman, DKMS Global, Jason Westin, MD, Director, Lymphoma Clinical Research, MD Anderson Cancer Center, American Society of Hematology The Leukemia & Lymphoma Society International Myeloma Foundation Lymphoma Research Foundation MPN Research Foundation MD Anderson Cancer Center American Society of Clinical Oncology (ASCO) GVHD Alliance DKMS Group GSK Allogene Therapeutics Children's Hospital Colorado Sobi - North America

Learn how our experience and differentiated science is enabling us to design and develop a CAR T 2.0 product for autoimmune disease that is scalable and could?eliminate or reduce lymphodepletion to meet the unique needs of patients. $ALLO #CART #celltherapy #immunotherapy Uncover the Potential of ALLO-329:?Allogene.com/Pipeline

At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR?T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy Explore Innovation at Allogene:?Allogene.com/Science

We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO?#CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design:?Allogene.com/Pipeline

Investigational AlloCAR?T? products are designed to overcome limitations of today’s autologous therapies and deliver these transformative treatments?to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy Explore the Potential of Expanded CAR T Access:?Allogene.com/Pipeline?

Pleased to report our Q4 and full year 2024 corporate update and business highlights. View our Q4 and Full Year 2024 update: https://lnkd.in/g4uCrE7Q

In case you missed it. Check out our webcast from the TD Cowen 45th Annual Health Care Conference. You can access the webcast here:?https://lnkd.in/eBV4zW9?#Biotech #CART #celltherapy #immuotherapy

Join us for our Q4 and full year 2024 conference call on Thursday, March 13 at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of?our website.?https://lnkd.in/gepuZBj3 $ALLO #Biotech #CART #celltherapy #immuotherapy?

Join us for our Q4 and full year 2024 conference call on March 13th at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of our website. Tune in for our quarterly call: https://lnkd.in/gepuZBj3